Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CCR8 | P51685 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30200047 | 0.92 | ALDH1A1 (0.42) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL15202095 | 0.83 | ALDH1A1 (0.42) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL32667194 | 0.81 | OPRM1 (0.38) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL28118056 | 0.81 | OPRM1 (0.38) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL8539678 | 0.80 | ALDH1A1 (0.40) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL22263381 | 0.77 | ALDH1A1 (0.38) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL12533662 | 0.76 | OPRM1 (0.49) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL12533655 | 0.76 | OPRM1 (0.49) | ALDH1A1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL900225 | 0.76 | — | — | |
| SCHEMBL3392695 | 0.76 | OPRM1 (0.49) | ALDH1A1NPC1RAB9AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016142952-A1 | PROCESS FOR PREPARATION OF VILAZODONE AND ITS NOVEL INTERMEDIATES | NOSCH LABS PRIVATE LIMITED (IN) | 2016-09-15 | — | — | WO | claimed |
| CN-117986153-A | Ionizable cationic lipid compound, and preparation method and application thereof | 晟迪生物医药(苏州)有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-1373204-B1 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016142952-A1 | PROCESS FOR PREPARATION OF VILAZODONE AND ITS NOVEL INTERMEDIATES | NOSCH LABS PRIVATE LIMITED (IN) | 2016-09-15 | — | — | WO | disclosed |
| EP-2598469-B1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | ESTEVE QUÍMICA S A (ES) | 2014-07-23 | — | — | EP | disclosed |
| EP-2598469-A1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | Esteve Química, S.A. (ES) | 2013-06-05 | — | — | EP | disclosed |
| EP-2418192-A1 | Intermediates for the preparation of 1-aryl-pyrazol-3-one compounds useful as sigma receptors inhibitors | Esteve Química, S.A. (ES) | 2012-02-15 | — | — | EP | disclosed |
| WO-2012013755-A1 | PROCESS FOR THE PREPARATION OF 1-ARYL-PYRAZOL-3-ONE INTERMEDIATES USEFUL IN THE SYNTHESIS OF SIGMA RECEPTORS INHIBITORS | Esteve Química, S.A. (ES) | 2012-02-02 | — | — | WO | disclosed |
| US-8030496-B2 | Intermediate compound for synthesis of viridiofungin a derivative | CHUGAI SEIYAKI KABUSHIKI KAISHA (JP) | 2011-10-04 | — | — | US | disclosed |
| US-7897783-B2 | Intermediate compound for synthesis of viridiofungin a derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | disclosed |
| WO-2002012224-A2 | BICYCLIC COMPOUNDS AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012190-A2 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012214-A2 | NON-IMIDAZOLE ARYLOXYALKYLAMINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARMACEUTICAL INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-01-17 | — | — | US | disclosed |
| US-20010051632-A1 | Phenyl-substituted indolizines and tetrahydroindolizines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2001-12-13 | — | — | US | disclosed |
| US-20010044439-A1 | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2001-11-22 | — | — | US | disclosed |
| WO-2001074814-A1 | PHENYL-SUBSTITUTED INDOLIZINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 LIGANDS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001074815-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001074813-A2 | METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| WO-2001074810-A2 | METHOD FOR USING 2-ARYLOXYALKYLAMINOBENZOXAZOLES AND 2-ARYLOXYALKYLAMINOBENZOTHIAZOLES AS H3 ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044439-A1 | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as H3 antagonists | HRH3, HRH4, HRH2 | ALDH1A1 1270/4885NPC1 3490/4885RAB9A 4807/4885 |
| US-20010051632-A1 | Phenyl-substituted indolizines and tetrahydroindolizines | TPH2, TPH1, IDO2 | ALDH1A1 967/4885NPC1 1122/4885RAB9A 3920/4885 |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | ALDH1A1 767/4885NPC1 323/4885RAB9A 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.